NASDAQ:CTIC - CTI BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.82 -0.01 (-0.55 %)
(As of 08/21/2018 01:51 AM ET)
Previous Close$1.83
Today's Range$1.75 - $1.87
52-Week Range$1.75 - $5.36
Volume498,200 shs
Average Volume498,490 shs
Market Capitalization$113.08 million
P/E Ratio-1.48
Dividend YieldN/A
Beta-0.32
CTI BioPharma logoCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTIC
CUSIPN/A
Phone206-282-7100

Debt

Debt-to-Equity Ratio0.18
Current Ratio4.28
Quick Ratio4.28

Price-To-Earnings

Trailing P/E Ratio-1.48
Forward P/E Ratio-3.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.15 million
Price / Sales4.20
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book5.20

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-40,670,000.00
Net Margins-313.77%
Return on Equity-90.92%
Return on Assets-49.12%

Miscellaneous

Employees57
Outstanding Shares57,990,000
Market Cap$113.08 million

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma's stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) issued its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.03. The biopharmaceutical company earned $0.61 million during the quarter, compared to analysts' expectations of $0.30 million. CTI BioPharma had a negative net margin of 313.77% and a negative return on equity of 90.92%. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

5 equities research analysts have issued 12-month price objectives for CTI BioPharma's shares. Their forecasts range from $4.00 to $10.00. On average, they expect CTI BioPharma's share price to reach $6.40 in the next twelve months. This suggests a possible upside of 251.6% from the stock's current price. View Analyst Price Targets for CTI BioPharma.

What is the consensus analysts' recommendation for CTI BioPharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.

What are Wall Street analysts saying about CTI BioPharma stock?

Here are some recent quotes from research analysts about CTI BioPharma stock:
  • 1. According to Zacks Investment Research, "CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington. " (7/24/2018)
  • 2. Cann analysts commented, "CTI BioPharma released Q4 2017 results today with lower-than-expected sales and slightly higher-than-estimated SG&A. Total revenue of $462,000 was lower than our estimated $1.7 million. All revenue was from License and Contract Revenue. Total operating expenses of $14.2 million were 6.3% higher than our estimated $13.3 million due to higher-than-estimated SG&A expense. CTI BioPharma lost $0.33 per share compared to our estimated loss per share of $0.28. Our 2018–2024 outlook is basically unchanged for CTI BioPharma. Programs are advancing, with data expected in H1 2018." (3/7/2018)

Who are some of CTI BioPharma's key competitors?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:
  • Dr. Adam R. Craig, Pres, CEO & Director (Age 52)
  • Dr. Jack W. Singer, Co-Founder, Exec. VP, Chief Scientific Officer, Interim CMO & Global Head-Translational Medicine (Age 75)
  • Mr. David H. Kirske, Exec. VP & CFO (Age 64)
  • Mr. Bruce J. Seeley, COO, Exec. VP & Sec. (Age 54)
  • Mr. Ed Bell, Sr. Director of Investor Relations

Has CTI BioPharma been receiving favorable news coverage?

Media stories about CTIC stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CTI BioPharma earned a daily sentiment score of 0.15 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for CTI BioPharma.

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (6.98%), BlackRock Inc. (4.83%), Renaissance Technologies LLC (1.33%), Millennium Management LLC (1.17%), Algert Global LLC (0.38%) and Opaleye Management Inc. (0.28%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Which major investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Millennium Management LLC. View Insider Buying and Selling for CTI BioPharma.

Which major investors are buying CTI BioPharma stock?

CTIC stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Algert Global LLC, Opaleye Management Inc., Alambic Investment Management L.P., Schwab Charles Investment Management Inc., Bank of New York Mellon Corp, Renaissance Technologies LLC and Alps Advisors Inc.. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $1.82.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $113.08 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-40,670,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. CTI BioPharma employs 57 workers across the globe.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (NASDAQ CTIC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel